Gore M, et al. - In a multicenter randomized factorial trial (UK and US), researchers assessed four treatment regimens for advanced-stage mucinous epithelial ovarian cancer: paclitaxel-carboplatin, oxaliplatin-capecitabine, paclitaxel-carboplatin-bevacizumab, or oxaliplatin-capecitabine-bevacizumab. Based on the findings, they concluded that oxaliplatin/capecitabine might be worth further investigation. In rare tumors, it was feasible to perform long-term follow-up. This study (mEOC/GOG0241) is an illustration of a randomized rare tumor trial. Lack of local resources and funding for experimental licenced therapies were encountered as challenges. Early termination was done due to logistical challenges faced, including difficulties in local histopathological diagnosis and accessing drugs outside their labelled indication. Inclusion of centralised pathology review prior to therapy in rare cancer trials was recommended.